What Is the Life Expectancy After ECMO?

Life expectancy after ECMO depends heavily on the reason the machine was needed, the type of ECMO used, and whether the patient survives the first month. Roughly a third of all adults placed on ECMO for heart failure are alive five years later, and the figure is slightly higher for those supported for lung failure. But those numbers shift dramatically once a patient clears the initial recovery period: among those who survive the first 30 days, about seven in ten are still alive at five years. That early-versus-late divide is the single most important thing to understand about post-ECMO life expectancy, and it shapes nearly every conversation about long-term outlook.

How Survival Differs Between VA-ECMO and VV-ECMO

ECMO comes in two main forms. Veno-arterial (VA) ECMO takes over both heart and lung function and is used when the heart is failing. Veno-venous (VV) ECMO supports only the lungs and is used for severe respiratory failure. The distinction matters because the underlying condition drives most of the risk.

A large study tracking both groups found that five-year survival was about 33% for VA-ECMO patients and 36% for VV-ECMO patients when counting everyone who was placed on the device.¹ A review of VV-ECMO outcomes specifically found that roughly three-quarters of patients survive the ECMO run itself and that many eventually return to daily life with relatively minor respiratory limitations.² VA-ECMO, by contrast, tends to carry steeper early mortality because the heart conditions it treats are often more immediately life-threatening. One single-center study found that only about 34% of VA-ECMO patients were alive at 30 days, and about 26% at one year.³

Why the First Month Changes Everything

The raw survival percentages look grim until you realize that most deaths happen very early, often while the patient is still in the hospital or shortly after discharge. A patient who makes it through the first 30 days has already cleared the highest-risk window. Among 30-day survivors, the five-year survival rate jumps to roughly 73% for VA-ECMO and 71% for VV-ECMO.¹ That is a fundamentally different prognosis from the overall numbers, and it is the figure that matters most for patients and families trying to plan ahead.

The leading causes of in-hospital death after a patient has been weaned off VA-ECMO help explain why early mortality is so concentrated. A study of patients who died after successful weaning found that cardiovascular causes accounted for about 32% of deaths, infections for 25%, and neurological complications for about 21%.⁴ In other words, even getting off the machine does not guarantee that the underlying organ damage has resolved. The heart may fail again, a secondary infection may take hold, or a stroke or brain bleed that occurred during support may prove fatal. Once those acute threats pass, survival curves flatten out considerably.

Children Have Their Own Trajectory

Pediatric ECMO outcomes follow a broadly similar pattern of high early attrition followed by stabilization, but the numbers differ. A population-based study of critically ill children found that about 56% survived to hospital discharge, dropping to roughly 50% at two years and 42% at five years.⁵ A smaller single-center study reported a one-year survival rate of 44%, with about a third of survivors developing a new medical problem after treatment.⁶

Among the children who made it to one year in that study, roughly 42% had recovered completely, while the remaining 58% showed mild to moderate communication or motor difficulties. These developmental outcomes are a particular concern in pediatric ECMO because children’s brains and bodies are still growing. A period of low blood flow or oxygenation during ECMO can leave marks that are not always visible until a child reaches milestones in speech, coordination, or learning.

Functional Recovery in the First Year

Surviving ECMO is one thing; getting back to normal life is another. A prospective multicenter study tracking VA-ECMO patients over 12 months found that about 71% had either died or developed a new disability by the one-year mark.⁷ That figure includes both the patients who died and those who survived with lasting impairment, so it paints a broad picture of the overall burden. The encouraging side of that study was the trajectory among survivors: the proportion who were independent in daily activities climbed from about 48% at six months to 62% at one year, and the share who were unemployed due to health reasons fell from roughly 47% to 33% over the same period. Recovery, for those who make it, keeps happening well past discharge.

Muscle weakness is a major barrier to that recovery. Patients who spend weeks sedated on ECMO frequently wake up unable to move their limbs at all. In a rehabilitation study of COVID-19 survivors who had been on ECMO, some patients had zero detectable muscle contraction upon waking. With intensive rehabilitation over about two weeks in the ICU, most regained meaningful strength, though scores at discharge still varied widely.⁸ The longer a patient stayed on ECMO and the longer they were intubated, the weaker their muscles tended to be afterward. This kind of acquired weakness can take months of outpatient physical therapy to overcome and is one reason the return to independent living is so gradual.

Kidney Function After ECMO

The kidneys take a particular beating during ECMO. Many patients need continuous dialysis while on support because their kidneys shut down from the underlying illness, low blood pressure, or the inflammatory response triggered by the circuit. Among those who needed both ECMO and dialysis and survived hospitalization, about 77% recovered enough kidney function to come off dialysis before leaving the hospital.⁹ The roughly one-quarter who were still dialysis-dependent at discharge were not necessarily stuck permanently: most of that group eventually regained kidney function too, though it took a median of about seven weeks.

Even when kidneys recover enough to stop dialysis, the long-term risk of chronic kidney disease remains elevated. A cohort study found that ECMO patients who developed severe kidney injury requiring dialysis during their hospitalization had about double the risk of a major adverse kidney event over the following years compared to ECMO patients whose kidneys held up. That included substantially higher rates of new chronic kidney disease and a dramatically increased risk of reaching end-stage kidney failure.¹⁰ For survivors, this means kidney function is worth monitoring for years after ECMO, even if it looked fine at discharge.

The Neurological and Psychological Aftermath

Brain-related complications are among the most feared consequences of ECMO, and they extend well past the acute phase. A systematic review and meta-analysis pooling data across multiple studies found that about 38% of ECMO survivors showed some degree of neurocognitive impairment.¹¹ This encompasses a range of problems including memory difficulties, trouble concentrating, and slower processing speed. Some of this may stem from the critical illness itself rather than from ECMO specifically, and teasing apart those causes is genuinely difficult.

Mental health is also affected in ways that can persist for years. A meta-analysis focused on trauma-related conditions estimated that about 19% of adult ECMO survivors develop PTSD, 30% experience anxiety, and 24% develop depression.¹² One study looking specifically at VA-ECMO patients reported that up to about 29% had PTSD symptoms.¹³ These numbers are roughly in line with what is seen in other intensive-care survivors, but the sheer severity of an ECMO stay, which often involves prolonged sedation, hallucinations, delirium, and sometimes awareness of being connected to the machine, may intensify the psychological toll. Studies of quality of life in ECMO survivors consistently note that while many achieve functional independence, a substantial portion continue to struggle with depression, anxiety, cognitive impairment, and difficulty returning to work or social activities.¹⁴

ECMO as a Bridge to Transplant

For some patients, ECMO is not meant to give the failing organ time to recover on its own. Instead, it keeps the patient alive long enough to receive a donor organ. In the context of lung transplantation, ECMO has become an increasingly common bridge, and the survival statistics look different from those for ECMO used as standalone therapy. A narrative review of the bridge-to-transplant literature found that one-year survival after transplant ranged from about 46% to 97%, and three-year survival from about 53% to 95%.¹⁵ The enormous variation reflects differences between centers in patient selection, the type of ECMO cannulation used, post-transplant complication rates, and how experienced each hospital is with the procedure. At high-volume centers, outcomes tend to cluster toward the better end of that range.

Because the transplant itself resets the patient’s organ function in a way that ECMO-as-recovery cannot, the long-term outlook for bridge patients who receive their organ and survive the perioperative period is fundamentally different. Their life expectancy is shaped more by the transplant than by the ECMO run that preceded it.

Readmissions and Financial Reality

Even survivors who are doing well clinically tend to cycle back through the hospital. A review of health resource use among ECMO survivors found that 30-day readmission rates ranged from 10% to about 44% across studies, and one-year readmission rates were as high as 61%.¹⁶ These readmissions are not always for the original problem. Infections, wound complications from cannulation sites, heart failure exacerbations, and new organ dysfunction all contribute.

The costs are staggering. That same review found that the mean cost of a 30-day readmission across studies was about $62,000, and total healthcare costs from the initial ECMO admission through one year ranged from roughly $190,000 to $244,000 on average. A South Korean study reported a median one-year total healthcare cost of about $46,000, with every additional $1,000 in that first-year spending associated with a slightly higher three-year mortality risk, probably because sicker patients simply cost more to treat.¹⁷ For families already strained by a catastrophic illness, these costs can be financially devastating. In a qualitative study of ECMO survivors, one patient described the immense financial pressure of an extended ICU stay on a rural family, and how that burden pushed them back into the workforce before they were physically ready.¹⁸

How ECMO Affects the People Around the Patient

Life expectancy and recovery statistics focus on the patient, but the experience radiates outward. A prospective study of family members of ECMO patients found that anxiety was highest during the treatment period and decreased somewhat over time, but that overall health-related quality of life, especially mental health, was severely affected and did not improve even after the patient recovered or died.¹⁹ The meta-analysis of trauma-related conditions found that 25% of adult ECMO patients’ family members developed PTSD, 67% experienced anxiety, and 50% experienced depression.¹²

Those family numbers are, in some cases, worse than the patients’ own rates. The anxiety prevalence of 67% among families of adult ECMO patients is more than double the 30% rate seen in the patients themselves. Part of this may stem from the helplessness of watching someone connected to a machine that is literally keeping them alive, combined with the uncertainty about whether recovery will come. Part of it may be that patients who are sedated during the worst of the ordeal do not form the same traumatic memories that their loved ones do. For families of pediatric patients, the numbers were somewhat lower but still considerable: about 21% developed PTSD, 46% had anxiety, and 32% experienced depression. Whatever the age of the patient, the psychological burden on families is a real and underappreciated part of the ECMO experience, and it tends to persist long after the machines are turned off and the patient is home.